Clinical trials: Autoimmune Anemia
Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
Cold Agglutinin Disease Real World Evidence Registry
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS).
- Trial name
- CADENCE (NCT05791708)
- Testing
- Sutimlimab
- Where
- 68 sites in United States, Austria and 6 more
- Volunteers
- 429 people
- Sponsor
- RECORDATI GROUP
IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
The study is being conducted to evaluate the effect of food on pharmacokinetics of HRS-5965 capsules after oral administration.
- Trial name
- NCT07035665
- Testing
- HRS-5965 Capsules
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia
The Internal Medicine Department of Haut-Lévêque Hospital (Pr E LAZARO, Pr JL PELLEGRIN, Pr JF VIALLARD) was accredited in 2017 by the Ministry of Health as a Constitutive Reference Center for Autoimmune Cytopenia.
- Conditions
- Immune Thrombocytopenia, Autoimmune Hemolytic Anemia, Autoimmune Neutropenia
- Trial name
- BIOCAI (NCT04005638)
- Testing
- blood sample, urine sample
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Bordeaux
Refractory Cold Agglutinin Disease
Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
This multicenter, phase II, open label study will enroll patients with chronic cold agglutinin disorder. A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11.
- Trial name
- CAD0111 (NCT01696474)
- Testing
- Bortezomib
- Where
- 8 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia
Patients of relapsed and refractory warm autoimmune hemolytic anemia or EVANS syndrome aged 18 to 80 will be included in this study.
- Trial name
- RRAIHA01 (NCT04083014)
- Testing
- combination of a single dose anti-CD20 antibody and bortezomib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking Union Medical College Hospital
Warm Autoimmune Hemolytic Anemia
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glucocorticoid (combined with rituximab) is the first-line treatment.
- Trial name
- NCT05922839
- Testing
- Zanubrutinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Chen Miao
Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).
- Trial name
- NCT07603557
- Testing
- BMS-986353, Fludarabine Phosphate, Cyclophosphamide
- Where
- 8 sites in United States, Denmark and 2 more
- Volunteers
- 52 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Warm Autoimmune Hemolytic Anemia (wAIHA)
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia
The purpose of this study is to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),
- Trial name
- PATHWAY (NCT05073458)
- Testing
- parsaclisinib
- Where
- 56 sites in United States, Austria and 11 more
- Volunteers
- 13 people
- Sponsor
- Incyte Corporation
Chronic Lymphocytic Leukemia
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00309881
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 18 sites in Germany
- Volunteers
- 75 people
- Sponsor
- German CLL Study Group
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and…
- Conditions
- Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
- Trial name
- NCT05757570
- Testing
- Povetacicept
- Where
- 44 sites in United States, Australia and 8 more
- Volunteers
- 30 people
- Sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex
Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
This is a prospective, multicenter, single-arm, pilot study. The aim of this study is to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for autoimmune hemolytic anemia patients who failed the second…
- Trial name
- NCT05676697
- Testing
- Linperlisib
- Where
- 2 sites in China
- Volunteers
- 4 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune
Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
The purpose of this study is to determine whether the combination of low doses of alemtuzumab and rituximab are effective in the treatment of patients with autoimmune cytopenias who has failed on steroids, relapsed after steroids…
- Trial name
- NCT00749112
- Testing
- Alemtuzumab, Rituximab
- Where
- Mexico
- Volunteers
- 19 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Autoimmune Hemolytic Anemia
A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia
wAIHA or EVANS syndrome: Linpriril 40mg, oral, once daily. The therapeutic effect will be evaluated after 4 weeks. If the therapeutic effect does not reach the PR, the dose will be increased to 60mg once a day.
- Trial name
- NCT07149818
- Testing
- Parsaclisib
- Volunteers
- 22 people
- Sponsor
- Peking Union Medical College Hospital
Asthma, Atrial Fibrillation
The Living With a Long-Term Condition Study
Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs).
- Conditions
- Asthma, Atrial Fibrillation, Cancer, Cerebrovascular Disorders
- Trial name
- LTC (NCT06072287)
- Testing
- Living with LTC Questionnaire
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- King's College London
Immunosuppresion, Thrombocytopenia
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular bone marrow.
- Conditions
- Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
- Trial name
- NCT00260689
- Testing
- Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Warm Autoimmune Hemolytic Anemia (wAIHA)
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.
- Trial name
- VAYHIA (NCT05648968)
- Testing
- Ianalumab
- Where
- 53 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals
Autoimmune Hemolytic Anemia
A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 STAR-T cell therapy in…
- Trial name
- NCT07075484
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 7 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Autoimmune Hemolytic Anemia, CD19 CAR-T Cell Infusion
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
To Evaluate the Safety and Efficacy of ThisCART19A for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy
- Trial name
- NCT06212154
- Testing
- ThisCART19A
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc